

SAFETY DATA SHEET



* 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	BACTROBAN NASAL											
Synonym(s)	BACTROBAN NASAL (MUPIROCIN CALCIUM OINTMENT, 2%) * BACTROBAN NASAL OINTMENT 2% * TURIXIN NASAL OINTMENT * TURIXIN NASENSALBE * MUPIROCIN CALCIUM * MUPIROCIN CALCIUM, FORMULATED PRODUCT											
Recommended Use	Medicinal Product											
Note	This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.											
Company Name	<p>GlaxoSmithKline UK 980 Great West Road Brentford, Middlesex TW8 9GS UK UK General Information (normal business hours): +44-20-8047-5000</p> <p>GlaxoSmithKline US 5 Moore Drive Research Triangle Park, NC 27709 USA US General Information (normal business hours): +1-888-825-5249</p> <p>Email Address: msds@gsk.com Website: www.gsk.com</p> <p>EMERGENCY PHONE NUMBERS -</p> <p>TRANSPORT EMERGENCIES (by country / geographic region):</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 80%;">Africa / EU / Israel / Middle East (English / European languages):</td> <td style="text-align: right;">+44 (0) 1235 239 670</td> </tr> <tr> <td>Asia Pacific (except China):</td> <td style="text-align: right;">+65 3158 1074</td> </tr> <tr> <td>China:</td> <td style="text-align: right;">+86 10 5100 3039</td> </tr> <tr> <td>Middle East / Africa (Arabic-speaking countries):</td> <td style="text-align: right;">+44 (0) 1235 239 671</td> </tr> <tr> <td>US:</td> <td style="text-align: right;">+1 703 527 3887</td> </tr> </table> <p>available 24 hrs/7 days; multi-language response</p> <p>MEDICAL EMERGENCIES: +1 612 221 3999, Ext 221 available 24 hrs/7 days; multi-language response</p>		Africa / EU / Israel / Middle East (English / European languages):	+44 (0) 1235 239 670	Asia Pacific (except China):	+65 3158 1074	China:	+86 10 5100 3039	Middle East / Africa (Arabic-speaking countries):	+44 (0) 1235 239 671	US:	+1 703 527 3887
Africa / EU / Israel / Middle East (English / European languages):	+44 (0) 1235 239 670											
Asia Pacific (except China):	+65 3158 1074											
China:	+86 10 5100 3039											
Middle East / Africa (Arabic-speaking countries):	+44 (0) 1235 239 671											
US:	+1 703 527 3887											

2. HAZARDS IDENTIFICATION

Fire and Explosion Hazards

This product is combustible.

Health

Caution - Pharmaceutical agent.

Not expected to be a significant health hazard unless product is spilt.

Possible effects of overexposure in the workplace include: irritation; itching; rash; symptoms of hypersensitivity (such as skin rash, hives, itching).

Health effects information is based on hazards of components.

Exposure might occur via ingestion; skin; eyes.

Environment

No information is available about the potential of this product to produce adverse environmental effects.

Material BACTROBAN NASAL

* 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
CALCIUM MUPIROCIN DIHYDRATE	115074-43-6	2	
Other components below reportable levels		98	

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Using appropriate personal protective equipment, move exposed subject to fresh air. If breathing is difficult or ceases, ensure and maintain ventilation. Give oxygen as appropriate. The exposed subject should be kept warm and at rest. Obtain medical attention in cases of known or possible over exposure, or with symptoms including chest pain, difficulty breathing, loss of consciousness or other adverse effects, which may be delayed.
Skin contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.
Health Surveillance Procedures	Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	Not expected for the product, although the packaging is combustible.
Extinguishing Media	Water is recommended for fires involving packaging.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	Detergent solutions can be used for clean-up and decontamination operations. No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
-----------------------------	--

Material BACTROBAN NASAL

STORAGE No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OCCUPATIONAL EXPOSURE LIMITS

INGREDIENT MUPIROCIN CALCIUM
GSK Occupational Hazard Category 1
GSK Occupational Exposure Limit 5000 mcg/m³ (8 HR TWA)

ENGINEERING CONTROLS

Exposure Controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.

Other Equipment or Procedures Wash hands and arms thoroughly after handling. None required for normal handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form Ointment.

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects This product contains active ingredient(s) with the following activity: an antibiotic.

Target Organ Effects No specific target organ effects have been identified.

Routes of Exposure

Oral Toxicity Not expected to be toxic following ingestion.
Assessment based upon effects of individual components.

Inhalation Toxicity No studies have been conducted.

Skin Effects Irritation is not expected following direct contact.
Assessment based upon effects of individual components.

Eye Effects Minor irritation might occur following direct contact with eyes.
Assessment based upon effects of individual components.

Sensitisation Sensitisation (allergic skin reaction) is not expected.
Assessment based upon effects of individual components.

Genetic Toxicity Not expected to be genotoxic, based on effects of individual components.

Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects No adverse effects have been reported following extensive use or exposure in humans. No components are identified as having adverse effects on the development of unborn offspring.

Other Adverse Effects The following adverse effects have been noted with therapeutic use of this material: irritation; rash; symptoms of hypersensitivity (such as skin rash, hives, itching).

12. ECOLOGICAL INFORMATION

Summary No information is available about the potential of this product to produce adverse environmental effects. Local regulations and procedures should be consulted prior to environmental release.

Material BACTROBAN NASAL

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Regulatory Requirements	Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Not regulated in transport.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 17

SDS Sections Updated**Sections**

COMPOSITION / INFORMATION ON INGREDIENTS
IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF
COMPANY

Subsections

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.